William Blair Weighs in on Penumbra’s Q1 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN) – William Blair boosted their Q1 2025 earnings per share estimates for Penumbra in a research note issued on Thursday, October 31st. William Blair analyst M. Kaczor now expects that the company will earn $0.79 per share for the quarter, up from their previous estimate of $0.72. The consensus estimate for Penumbra’s current full-year earnings is $2.58 per share. William Blair also issued estimates for Penumbra’s Q2 2025 earnings at $1.00 EPS.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.16. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. The company had revenue of $301.04 million for the quarter, compared to analysts’ expectations of $297.36 million. During the same period in the prior year, the firm earned $0.67 earnings per share. The firm’s revenue was up 11.1% compared to the same quarter last year.

A number of other research firms have also issued reports on PEN. Wells Fargo & Company lowered Penumbra from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $289.00 to $150.00 in a report on Wednesday, July 31st. Royal Bank of Canada boosted their target price on Penumbra from $205.00 to $222.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Citigroup boosted their target price on Penumbra from $178.00 to $200.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Piper Sandler boosted their target price on Penumbra from $225.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, BTIG Research boosted their target price on Penumbra from $224.00 to $234.00 and gave the company a “buy” rating in a report on Monday, October 14th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $226.67.

Penumbra Stock Down 1.6 %

NYSE:PEN opened at $229.51 on Monday. The stock has a market capitalization of $8.81 billion, a price-to-earnings ratio of 266.87, a price-to-earnings-growth ratio of 2.62 and a beta of 0.51. The stock’s fifty day moving average is $201.36 and its two-hundred day moving average is $193.93. Penumbra has a 52 week low of $148.00 and a 52 week high of $277.34. The company has a quick ratio of 3.77, a current ratio of 5.82 and a debt-to-equity ratio of 0.02.

Penumbra announced that its board has initiated a share repurchase plan on Tuesday, August 13th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Insider Activity at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $175.98, for a total transaction of $105,588.00. Following the transaction, the executive vice president now owns 61,688 shares in the company, valued at approximately $10,855,854.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Adam Elsesser sold 1,620 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $200.00, for a total transaction of $324,000.00. Following the sale, the chief executive officer now owns 925,962 shares of the company’s stock, valued at $185,192,400. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $175.98, for a total value of $105,588.00. Following the sale, the executive vice president now directly owns 61,688 shares in the company, valued at $10,855,854.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,368 shares of company stock worth $6,893,118 in the last quarter. Company insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Penumbra

Several institutional investors have recently modified their holdings of PEN. Champlain Investment Partners LLC boosted its stake in shares of Penumbra by 131.8% during the 1st quarter. Champlain Investment Partners LLC now owns 1,084,595 shares of the company’s stock worth $242,060,000 after acquiring an additional 616,700 shares in the last quarter. AQR Capital Management LLC lifted its stake in Penumbra by 439.8% in the 2nd quarter. AQR Capital Management LLC now owns 178,413 shares of the company’s stock valued at $31,283,000 after buying an additional 145,364 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Penumbra by 96.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 257,058 shares of the company’s stock valued at $46,257,000 after buying an additional 126,392 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Penumbra in the 2nd quarter valued at approximately $17,943,000. Finally, William Blair Investment Management LLC lifted its stake in Penumbra by 12.2% in the 1st quarter. William Blair Investment Management LLC now owns 833,703 shares of the company’s stock valued at $186,066,000 after buying an additional 90,444 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.